Heart failure & cardiomyopathies
Analysis of the PARAGON-HF Study Results Using Win Ratio
Primary resultResult — go to the resultWin ratio 1.13 95% CI 1.04–1.23Authors' conclusion
Employing the innovative win ratio approach, sacubitril-valsartan demonstrated significant clinical benefits among patients with HF with preserved ejection fraction. Notably, this benefit was observed irrespective of left ventricular ejection fraction and sex.
Study context
- Population
- Patients with HFpEF
- Participants
- 4,822 patients
- Comparison
- Sacubitril-valsartan vs valsartan
- Primary endpoint
- Hierarchical composite of:
- Time to CV death
- Total heart failure (HF) hospitalizations
- Time to first HF hospitalization
- Time to renal composite outcome
- Change in KCCQ total symptom score at 8 months
Methodological detailswin ratio analysis
- Win ratio analysis
Primary result
As reported in the abstract
Win ratio
1.13
95% CI 1.04–1.23
P = 0.005
Sacubitril-valsartanvs Valsartan
win ratio 1.13 (95% CI 1.04–1.23); P = 0.005
Further findings
Win ratio by LVEF (above vs below median 57%) and by sex (subgroups)
- Benefit regardless of LVEF above or below median (57%) and regardless of sex
- Interaction P=0.76 for LVEF
- Interaction P=0.73 for sex
Original publication
Analysis of the PARAGON-HF Study Results Using Win Ratio. Circ Heart Fail. Published 28 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →